Canada Silent Heart Attack Market to Reach $330.4 Million by 2035

Canada silent attack market was valued at $139.3 million in 2025 and is projected to reach $330.4 million by 2035, growing at a CAGR of 9.0% from 2026 to 2035. Market growth is driven by the increasing burden of cardiovascular diseases and the rising adoption of advanced diagnostic technologies. According to the World Health Organization (WHO), cardiovascular diseases account for nearly 19.8 million casualties annually worldwide, representing about 32% of total global mortality. This high disease burden is significantly increasing the need for early and incidental detection of silent myocardial infarction, particularly through ECG, cardiac biomarkers, and imaging technologies across hospitals and diagnostic centers in Canada.

Browse the full report description of “Canada Silent Heart Attack Market Size, Share & Trends Analysis Report by Diagnostic (ECG, Cardiac Biomarkers Testing, Cardiac Imaging, Wearable & Remote Monitoring Devices), by Treatment Type (Pharmacological Treatment, Interventional Procedures, Lifestyle & Preventive Management), by End-User (Hospitals, Cardiology Clinics, Diagnostic Centers, Homecare Settings), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/canada-silent-heart-attack-market

Competitive Landscape of the Canada Silent Heart Attack Market

The key players in the Canada silent heart attack market include top companies such as Cardinal Health, Pfizer, AstraZeneca, Abbott, and Medtronic, among others. The market is witnessing steady growth due to increased use of advanced diagnostic tools such as high-sensitivity troponin testing, cardiac imaging, and wearable monitoring devices. Hospitals and cardiology clinics are expanding diagnostic capabilities to detect asymptomatic cardiac events, improving patient outcomes and reducing long-term complications.

• In 2025, Biotricity expanded its cardiac diagnostics portfolio by advancing HeartSecure™, a continuous ECG monitoring solution that enables multi-day remote tracking of cardiac activity, improving detection of asymptomatic heart abnormalities linked to silent heart attacks.

Market Coverage

• The market number available for – 2025–2035
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-
• By Diagnostic
• By Treatment Type
• By End User
• Competitive Landscape: Cardinal Health, Pfizer, AstraZeneca, Abbott, and Medtronic, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Canada Silent Heart Attack Market Report Segment

By Diagnostic

• Electrocardiogram (ECG)
• Cardiac Biomarkers Testing (Troponin, CK-MB)
• Cardiac Imaging
• Wearable & Remote Monitoring Devices

By Treatment Type

• Pharmacological Treatment
• Interventional Procedures
• Lifestyle & Preventive Management

By End User

• Hospitals
• Cardiology Clinics
• Diagnostic Centers
• Homecare Settings

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/canada-silent-heart-attack-market